Healthcare Industry News: Incyte
News Release - January 30, 2007
Metabolon Expands Management TeamRESEARCH TRIANGLE PARK, N.C.--(HSMN NewsFeed)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery, today announced the appointment of three new members to the Metabolon executive staff.
Tim Germann, Metabolon's new Vice President of Sales, will drive growth and revenue through close alliances with pharmaceutical and biotechnology customers. Before arriving at Metabolon, Germann led sales and marketing at U.S. Genomics, where they launched the Trilogy® Single Molecule Analyzer. Prior to that, he was responsible for generating more than $30 million per year in revenue for Affymetrix where he helped to lead the Americas launch of the 10K, 100K, and 500K SNP arrays. Germann is an industry veteran, having also led sales efforts at Molecular Devices, Stratagene, and Incyte Genomics.
Dr. Bruce McCreedy has been appointed Vice President for Strategic Development and will drive the establishment of Metabolon's diagnostic business. He will establish strategic relationships to conduct clinical studies for the validation of diagnostic tests based on biomarkers discovered using Metabolon's core technology. McCreedy has over 19 years experience in healthcare and drug development. Previously, he served as Associate Vice President for Infectious Diseases with LabCorp, Vice President of Clinical Virology and Diagnostics with Triangle Pharmaceuticals, and CEO of Fulcrum Pharma Developments.
Dr. Dan Stevens, Metabolon's new Director of Marketing, is responsible for identification, development, and introduction of metabolomics solutions to the market. Trained as both a clinician and a research scientist, Stevens brings a diversity of knowledge about customer needs to the organization. He comes to Metabolon from Silicon Graphics, Inc. and Procter & Gamble where he successfully launched products that today are generating more than $100 million in revenue.
"Over the past five years, Metabolon has invested in developing the premier metabolmics platform," said John Ryals, president and CEO of Metabolon. "With the addition of these experienced executives, Metabolon is poised to expand its lead as the industry-leading provider of metabolomics services that improve drug discovery, development, and diagnostics."
Metabolon is the industry leader in the discovery of biomarkers through the use of metabolomics, a powerful scientific approach for the discovery and development of drugs and the early diagnosis of disease. Metabolon's patented technology dramatically impacts drug discovery and development processes by accurately measuring the spectrum of biochemical changes and mapping these changes to metabolic pathways. Metabolon's technology can identify safer compounds for development, shorten the time for drugs to get to market and identify novel biomarkers for earlier disease detection. In 2006, Metabolon was awarded a patent that broadly covers the metabolomic methods used to identify biomarkers seen in patients with amyotrophic lateral sclerosis (ALS). For additional information, visit www.metabolon.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.